Clincosm LogoSign in Get a demo

Incidence and Risk of Influenza in Myasthenic Patients

Sponsor
Centre d'Investigation Clinique et Technologique 805 (Other)
Overall Status
Completed
CT.gov ID
NCT03884777
Collaborator
(none)
400
Enrollment
108
Actual Duration (Months)

Study Details

Study Description

Brief Summary

Upper respiratory infection , including influenza, may exacerbate the symptoms of myasthenia gravis (MG), which is an autoimmune disease that causes muscle weakness and, in some cases, can precipitate a myasthenic crisis

In the present study, we investigated the incidence and risk factors of influenza infection on in myasthenia gravis patients.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This is a descriptive study. The data will be analyzed retrospectively . Inclusion of 416 cases of influenza in myasthenic patients treated in the intensive care unit of Garches Hospital between January 1, 2009 and December 31, 2017.

    Patients who meet the inclusion and non inclusion criteria and do not object to participate in the study will be collected in a database for analysis.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    400 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Incidence and Risk of Influenza in Myasthenic Patients Hospitalized in Intensive Care
    Actual Study Start Date :
    Jan 1, 2009
    Actual Primary Completion Date :
    Dec 31, 2017
    Actual Study Completion Date :
    Dec 31, 2017

    Outcome Measures

    Primary Outcome Measures

    1. Incidence of influenza in myasthenic patient in crisis [between January 1, 2009 and December 31, 2017.]

      Number of influenza cases in myasthenic patients

    Secondary Outcome Measures

    1. Risk factors for poor outcomes [between January 1, 2009 and December 31, 2017.]

      To identify risk factors for severe influenza in myasthenic patients

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • Men or women over the age of 18.

    • Myasthenic patients hospitalized in intensive care.

    • Patients with confirmed influenza infection

    Exclusion Criteria:

    • Age <18 years,

    • Other neuromuscular diseases,

    • Patient opposing the use of his data

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Centre d'Investigation Clinique et Technologique 805

    Investigators

    • Study Director: Rania BOUNAB, Dr, Raymond PoincarĂ© Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Centre d'Investigation Clinique et Technologique 805
    ClinicalTrials.gov Identifier:
    NCT03884777
    Other Study ID Numbers:
    • CIC1429
    First Posted:
    Mar 21, 2019
    Last Update Posted:
    Mar 21, 2019
    Last Verified:
    Dec 1, 2017
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Centre d'Investigation Clinique et Technologique 805
    Influenza A virus
    myasthenia gravis
    neurocritical care clinical
    neuromuscular disease
    Additional relevant MeSH terms:
    Influenza, Human
    Respiratory Tract Infections

    Study Results

    No Results Posted as of Mar 21, 2019